Bio-Rad

The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

The agreement, with Genetic Analysis of Oslo, involves technology to detect gut dysbiosis and investment for additional tests.

The test uses droplet digital PCR to detect BCR-ABL gene fusions and is intended for treatment response monitoring of chronic myeloid leukemia.

The Index significantly outperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index as it showed double the growth that it had displayed in October.

Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.

The reagent, which was tested on Bio-Rad's Droplet Digital PCR platform, could prove useful for quality control of clinical dPCR applications.

Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.